US11918565 — Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
Method of Use · Assigned to Pacira Pharmaceuticals Inc · Expires 2043-02-02 · 17y remaining
What this patent protects
This patent protects a method of administering a sustained-release liposomal anesthetic composition to a patient's sciatic nerve for post-operative pain relief.
USPTO Abstract
Provided herein are methods of administering to a peroneal and a tibial nerve of a patient, wherein the methods include: (a) selecting an entry point of an injection needle in a leg of a patient; (b) inserting the injection needle into the patient at the entry point; (c) administering to a sciatic nerve of the patient via the injection needle saline and a pharmaceutical composition; wherein the pharmaceutical composition comprises multivesicular liposomes comprising: at least one amphipathic lipid, at least one neutral lipid, and bupivacaine phosphate, wherein the bupivacaine phosphate is encapsulated within the multivesicular liposome.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3841 |
— | Bupivacaine Hydrochloride And Epinephrine |
U-3841 |
— | Bupivacaine Hydrochloride And Epinephrine |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.